Table 4 |
||||||
|
FMD, NMD and IMT in MCTD patients with/without cardiovascular disease and controls |
||||||
|
%FMDa |
P value |
%NMDa |
P value |
IMTa |
P value |
|
|
|
||||||
|
Age at investigation (years) |
-0.0221 |
0.878 |
-0.6700 |
0.001 |
0.5468 |
0.001 |
|
Disease duration (years) |
-0.6468 |
0.001 |
-0.1314 |
0.3628 |
0.1968 |
0.1706 |
|
Systolic blood pressure (mmHg) |
-0.5423 |
0.001 |
-0.1094 |
0.4492 |
0.2220 |
0.1211 |
|
Diastolic blood pressure (mmHg) |
0.0946 |
0.5133 |
0.1005 |
0.4872 |
-0.1597 |
0.2676 |
|
Serum triglycerides (mmol/l) |
-0.3396 |
0.0158 |
0.2165 |
0.1309 |
-0.0411 |
0.7765 |
|
Serum cholesterol |
-0.0459 |
0.7514 |
0.0508 |
0.7255 |
-0.0209 |
0.8851 |
|
Apolipoprotein A1 (g/l) |
0.6203 |
0.001 |
-0.0805 |
0.5782 |
-0.0248 |
0.8640 |
|
Apolipoprotein B (g/l) |
-0.3102 |
0.061 |
-0.0891 |
0.5997 |
0.0767 |
0.6517 |
|
Paraoxonase-1 activity |
0.5957 |
0.001 |
0.1317 |
0.3619 |
-0.2789 |
0.0497 |
|
hs-CRP |
-0.4057 |
0.003 |
-0.3207 |
0.023 |
0.7164 |
0.001 |
|
ESR |
-0.4283 |
0.001 |
-0.3981 |
0.001 |
0.5467 |
0.001 |
|
Anti-U1RNP (U/ml) |
-0.0486 |
0.7371 |
-0.0694 |
0.6316 |
0.4182 |
0.0025 |
|
Anti-CL IgG (U/ml) |
-0.0717 |
0.6206 |
-0.0411 |
0.776 |
0.2236 |
0.1184 |
|
AECA (IU/ml) |
-0.3075 |
0.029 |
-0.2686 |
0.0592 |
0.2890 |
0.0417 |
|
Thrombomodulin (ng/ml) |
-0.0642 |
0.6577 |
-0.0165 |
0.9089 |
0.4823 |
0.00038 |
|
vWFAg (%) |
-0.0122 |
0.9329 |
-0.2692 |
0.058 |
0.5443 |
0.001 |
|
|
||||||
|
AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; ESR, erythrocyte sedimentation rate; FMD, flow-mediated dilation; hs-CRP, high-sensitivity C-reactive protein; IMT, intima-media thickness; MCTD, mixed connective tissue disease; NMD, nitrate-mediated dilation; vWFAg, von Willebrand factor antigen. aSpearman rank correlation. |
||||||
|
Soltesz et al. Arthritis Research & Therapy 2010 12:R78 doi:10.1186/ar2999 |
||||||
